Page last updated: 2024-11-04

alminoprofen

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

alminoprofen: structure given in first source; RN given refers to parent cpd without isomeric designation [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

alminoprofen : A substituted aniline that is ibuprofen in which the isobutyl group is replaced by a (2-methylprop-2-en-1-yl)amino group. A non-steroidal anti-inflammatory drug, it is used for treatment of inflammatory and rheumatic disorders. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID2097
CHEMBL ID1765293
CHEBI ID31190
SCHEMBL ID26940
MeSH IDM0090409

Synonyms (62)

Synonym
CHEMBL1765293
chebi:31190 ,
minalfen
54362-71-9
alminoprofen, (-)-
alminoprofen
eb-382
minalfene
benzeneacetic acid, alpha-methyl-4-((2-methyl-2-propenyl)amino)-, (-)-
alminoprofeno [spanish]
alminoprofenum [inn-latin]
einecs 254-604-6
alminoprofene [inn-french]
2-(4-(methallylamino)phenyl)propionic acid
alpha-methyl-4-((2-methyl-2-propenyl)amino)benzeneacetic acid
2-(4-((2-methylallyl)amino)phenyl)propansaeure
propionic acid, 2-(4-(methallylamino)phenyl)-
acide (methallylamino-4 phenyl)-2 propionique [french]
4-((2-methylallyl)amino)hydratropasaeure
alminoprofen [inn:jan]
brn 2373633
p-((2-methylallyl)amino)hydratropic acid
alminoprofeno [inn-spanish]
eb 382
benzeneacetic acid, alpha-methyl-4-((2-methyl-2-propenyl)amino)-
alminoprofen (jp17/inn)
D01513
39718-89-3
minalfen (tn)
2-{4-[(2-methylprop-2-en-1-yl)amino]phenyl}propanoic acid
2-[4-(2-methylprop-2-enylamino)phenyl]propanoic acid
AKOS016014146
acide (methallylamino-4 phenyl)-2 propionique
alminoprofene
unii-0255ahr9gj
alminoprofeno
0255ahr9gj ,
alminoprofenum
alminoprofen, (+)-
2-{4-[(2-methylprop-2-en-1-yl)amino]phenyl}propionic acid
alpha-methyl-4-[(2-methyl-2-propenyl)amino]benzeneacetic acid
alminoprofen [jan]
alminoprofen [inn]
alminoprofen [mi]
alminoprofen [who-dd]
alminoprofen [mart.]
SCHEMBL26940
(+/-)-alminoprofen
2-(4-((2-methylallyl)amino)phenyl)propanoic acid
l-alminoprofen
Q3612806
DB13314
BCP11016
DTXSID90865968
(+/-)-alminoprofen;eb 382; minalfene
NCGC00522017-01
()-alminoprofen;eb 382; minalfene
eb382
AS-78318
CS-0009220
HY-17485
racalminoprofen-d3

Research Excerpts

Overview

Alminoprofen is a nonsteroidal anti-inflammatory drug (NSAID) of the phenylpropionic acid class. It is used as an analgesic for rheumatism.

ExcerptReferenceRelevance
"Alminoprofen is a non-steroid anti-inflammatory drug (NSAID) used as an analgesic for rheumatism."( Evaluation of anti-inflammatory drug-conjugated silicon quantum dots: their cytotoxicity and biological effect.
Fujioka, K; Futamura, Y; Hanada, S; Hoshino, A; Manabe, N; Yamamoto, K, 2013
)
1.11
"Alminoprofen is a nonsteroidal anti-inflammatory drug (NSAID) of the phenylpropionic acid class. "( Anti-inflammatory mechanism of alminoprofen: action on the phospholipid metabolism pathway.
Diab, N; Domage, G; Dray, F; Mace, JL; Raguenes-Nicol, C; Russo-Marie, F; Solito, E; Streichenberger, G, 1999
)
2.03

Pharmacokinetics

ExcerptReferenceRelevance
" The pharmacokinetic parameters after oral administration of Alminoprofen were analyzed by the one-compartment open model method."( [Pharmacokinetics of oral alminoprofen (Minalfen) in elderly patients with rheumatoid arthritis and spondylosis deformans].
Hirayama, H; Katsunuma, H; Sato, K; Sato, S; Shibuya, T; Shin, K; Takasaki, M, 1992
)
0.83
" The non-linear mixed effect model approach was used to estimate the mean and variance of the pharmacokinetic parameters."( A population pharmacokinetic study of alminoprofen penetration into synovial fluid.
Brion, N; Garcia-Mace, JL; Le Gros, V; Louchahi, K; Petitjean, O; Pobel, C; Tod, M, 1995
)
0.56

Dosage Studied

ExcerptRelevanceReference
"5 micrograms/ml, after dosing on day 1, 25."( [Pharmacokinetics of oral alminoprofen (Minalfen) in elderly patients with rheumatoid arthritis and spondylosis deformans].
Hirayama, H; Katsunuma, H; Sato, K; Sato, S; Shibuya, T; Shin, K; Takasaki, M, 1992
)
0.58
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (7)

RoleDescription
non-steroidal anti-inflammatory drugAn anti-inflammatory drug that is not a steroid. In addition to anti-inflammatory actions, non-steroidal anti-inflammatory drugs have analgesic, antipyretic, and platelet-inhibitory actions. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins.
antirheumatic drugA drug used to treat rheumatoid arthritis.
antipyreticA drug that prevents or reduces fever by lowering the body temperature from a raised state. An antipyretic will not affect the normal body temperature if one does not have fever. Antipyretics cause the hypothalamus to override an interleukin-induced increase in temperature. The body will then work to lower the temperature and the result is a reduction in fever.
EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitorA lipoxygenase inhibitor that interferes with the action of arachidonate 5-lipoxygenase (EC 1.13.11.34).
EC 3.1.1.4 (phospholipase A2) inhibitorAn EC 3.1.1.* (carboxylic ester hydrolase) inhibitor that interferes with the action of phospholipase A2 (EC 3.1.1.4).
cyclooxygenase 2 inhibitorA cyclooxygenase inhibitor that interferes with the action of cyclooxygenase 2.
non-narcotic analgesicA drug that has principally analgesic, antipyretic and anti-inflammatory actions. Non-narcotic analgesics do not bind to opioid receptors.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (4)

ClassDescription
monocarboxylic acidAn oxoacid containing a single carboxy group.
substituted aniline
amino acidA carboxylic acid containing one or more amino groups.
secondary amino compoundA compound formally derived from ammonia by replacing two hydrogen atoms by organyl groups.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (1)

Assay IDTitleYearJournalArticle
AID592681Apparent permeability across human Caco2 cell membrane after 2 hrs by LC-MS/MS analysis2011Bioorganic & medicinal chemistry, Apr-15, Volume: 19, Issue:8
QSAR-based permeability model for drug-like compounds.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (21)

TimeframeStudies, This Drug (%)All Drugs %
pre-199010 (47.62)18.7374
1990's7 (33.33)18.2507
2000's0 (0.00)29.6817
2010's3 (14.29)24.3611
2020's1 (4.76)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 25.71

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index25.71 (24.57)
Research Supply Index3.22 (2.92)
Research Growth Index4.26 (4.65)
Search Engine Demand Index29.35 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (25.71)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (4.35%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other22 (95.65%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]